Related references
Note: Only part of the references are listed.A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
A. R. Abdul Razak et al.
ANNALS OF ONCOLOGY (2013)
A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers
Carlo L. Bello et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1,-2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors
Toshiaki Takahashi et al.
INVESTIGATIONAL NEW DRUGS (2012)
Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
Pasi A. Jaenne et al.
CLINICAL CANCER RESEARCH (2011)
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Andrea J. Gonzales et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer
Stephane Temam et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas
Christine H. Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study
B Burtness et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review
A Trotti et al.
RADIOTHERAPY AND ONCOLOGY (2003)
Squamous cell carcinomas of the head and neck
RJ Sanderson et al.
BMJ-BRITISH MEDICAL JOURNAL (2002)
Share Paper
